| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | ML311 | CTRPv2 | pan-cancer | AAC | 0.071 | 0.03 |
| mRNA | BRD-A86708339 | CTRPv2 | pan-cancer | AAC | 0.11 | 0.03 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.081 | 0.03 |
| mRNA | Compound 23 citrate | CTRPv2 | pan-cancer | AAC | 0.073 | 0.03 |
| mRNA | BRD-K94991378 | CTRPv2 | pan-cancer | AAC | -0.085 | 0.03 |
| mRNA | StemRegenin 1 | CTRPv2 | pan-cancer | AAC | 0.073 | 0.03 |
| mRNA | BRD-K19103580 | CTRPv2 | pan-cancer | AAC | -0.078 | 0.03 |
| mRNA | ML210 | CTRPv2 | pan-cancer | AAC | -0.065 | 0.04 |
| mRNA | Doxorubicin | CTRPv2 | pan-cancer | AAC | 0.058 | 0.05 |
| mRNA | NVP-231 | CTRPv2 | pan-cancer | AAC | 0.063 | 0.05 |